Report Sections

See All Reports

  • HP:0002355: Difficulty walking
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002355: Difficulty walking

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (1)


    Name (Synonyms) Correlation
    drug2782 Remdesivir Wiki 0.17

    Correlated MeSH Terms (4)


    Name (Synonyms) Correlation
    D051346 Mobility Limitation NIH 1.00
    D000073496 Frailty NIH 0.41
    D045169 Severe Acute Respiratory Syndrome NIH 0.04
    Name (Synonyms) Correlation
    D018352 Coronavirus Infections NIH 0.04

    Correlated HPO Terms (0)


    Name (Synonyms) Correlation

    Clinical Trials

    Navigate: Correlations   HPO

    There is one clinical trial.


    1 Functional Recovery of Older Hospitalised Patients With COVID-19: a Prospective and Retrospective Cohort Study Extension to the Coronavirus Registry (COREG)

    Older adults and those with chronic underlying health conditions are the most susceptible to COVID-19 and its complications. Although there has been a rapid response to studying the effects of COVID-19 in the acute stages, little is known about recovery over the longer-term. Older adults who survive the diseases are at risk of developing persistent mobility limitations due to extensive bed rest during hospitalization. For older patients and those with underlying frailty recovering from COVID-19, this could rapidly lead to significant physical deconditioning and rapid declines in mobility. Understanding the trajectory of functional recovery of older hospitalised patients with COVID-19 in the short- and long-term is critical to improving patient outcomes and informing health and rehabilitative interventions for survivors.

    NCT04602260
    Conditions
    1. Covid19
    2. Corona Virus Infection
    3. Mobility Limitation
    4. Frailty
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Frailty Mobility Limitation
    HPO:Difficulty walking

    Primary Outcomes

    Description: The AM-PAC is an activity limitation instrument based on the International Classification of Functioning, Disability and Health (ICF) that assesses 3 functional domains: basic mobility, daily activities and applied cognition.

    Measure: Change in Activity Measure for Post Acute Care (AM-PAC) Basic Mobility Inpatient Version

    Time: Admission to hospital ward (0-14 days post ward admission) and discharge from hospital (0-14 days post discharge or up to 6 months, whichever comes first)

    Description: The AM-PAC is an activity limitation instrument based on the International Classification of Functioning, Disability and Health (ICF) that assesses 3 functional domains: basic mobility, daily activities and applied cognition.

    Measure: Change in Activity Measure for Post Acute Care (AM-PAC) Basic Mobility Outpatient Version

    Time: Admission to hospital ward (0-14 days post ward admission, to capture pre-morbid function), and at 3,6,9 and 12-months post hospital discharge

    Description: The AM-PAC is an activity limitation instrument based on the International Classification of Functioning, Disability and Health (ICF) that assesses 3 functional domains: basic mobility, daily activities and applied cognition.

    Measure: Change in Activity Measure for Post Acute Care (AM-PAC) Applied Cognitive Inpatient Version

    Time: Admission to hospital ward (0-14 days post ward admission) and discharge from hospital (0-14 days post discharge or up to 6 months, whichever comes first)

    Description: The AM-PAC is an activity limitation instrument based on the International Classification of Functioning, Disability and Health (ICF) that assesses 3 functional domains: basic mobility, daily activities and applied cognition.

    Measure: Change in Activity Measure for Post Acute Care (AM-PAC) Daily Activity

    Time: 3,6,9 and 12-months post hospital discharge

    Secondary Outcomes

    Description: The SPPB combines the results of gait speed over 3 meters, the 5-repetition chair-stand, and a progressive balance test to assess lower extremity function.

    Measure: Change in Short Physical Performance Battery (SPPB)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The CFS is an interview-based scale wherein the assessor may ask the patient questions about things such as their independence or physical abilities to determine where the patient falls along the 9-point scale, from 1 (Very Fit) to 9 (Terminally Ill).

    Measure: Change in Clinical Frailty Scale (CFS) for participants over 60 years of age

    Time: Admission to hospital ward (0-14 days post ward admission, to capture pre-morbid function ), and at 3,6,9 and 12-months post hospital discharge

    Description: The Forced Expiratory Volume in 1 Second parameter measures the volume of air that was exhaled into the mouthpiece in the first second after a full inhalation as measured by spirometry.

    Measure: Change in Forced Expiratory Volume (FEV1)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible, as measured by spirometry. FVC is the total amount of air exhaled during the FEV test.

    Measure: Change in Forced Vital Capacity (FVC)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The FEV1/FVC Ratio (FEV1%) parameter is calculated by dividing the measured FEV1 value by the measured FVC value.

    Measure: Change in Forced Expiratory Volume Percentage (FEV1%)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The BDI rates the severity of dyspnea at a single point in time (baseline) based on a 24-item interviewer administered rating scale.

    Measure: Baseline Dyspnea Index (BDI)

    Time: 3 months post hospital discharge

    Description: Measures changes in dyspnea severity from the baseline as established by the BDI.

    Measure: Change in Transition Dyspnea Index (TDI)

    Time: 6,9 and 12-months post hospital discharge

    Description: The PHQ-9 is a self-rating instrument for depression based on nine questions that the patient responds to by indicating how much they have been bothered by these symptoms over the last two weeks.

    Measure: Change in Patient Health Questionnaire - 9 (PHQ-9)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The FIM assesses the functional status of a person based on the level of assistance the person requires.

    Measure: Change in Functional Independence Measure (FIM)

    Time: 3 and 6 months post hospital discharge

    Description: The IES-R is a 22-item self-report measure that asks questions about subjective distress caused by traumatic events. Each item is rated on a 5-point scale, from 0 ("not at all") to 4 ("extremely").

    Measure: Change in Impact of Event Scale - Revised (IES-R)

    Time: 3,6,9 and 12-months post hospital discharge

    Description: The EQ-5D-5L is a generic and well-established instrument for describing health status or disease-specific outcome measures. It defines health in terms of five dimensions: Mobility, Self- Care, Usual Activities, Pain/Discomfort, and Anxiety/ Depression. The response options are of five levels, from no, slight, moderate, severe, to extreme problems

    Measure: Change in Health status (EQ-5D-5L)

    Time: 3,6,9 and 12-months post hospital discharge

    HPO Nodes


    HP:0002355: Difficulty walking
    Genes 304
    C12ORF65 EEF1A2 FBXO38 CRYAB GYG1 WASHC5 TRAPPC11 PLP1 VAMP1 NECAP1 NUBPL ERCC6 NEB CPT1C SMO ANO5 CNKSR2 TTN NTRK1 PDK3 GABRG2 SIGMAR1 TGM6 FKRP FKRP EIF2S3 GJC2 ATP13A2 CACNA1A STXBP1 ALG14 SLC30A10 PDGFB POMT1 RYR1 POMT1 AP4B1 PLP1 DNM1L ERCC6 AARS1 KCND3 SLC30A9 WWOX NKX2-1 ATP13A2 SYNJ1 HERC1 FKTN PSAP CPT1C PNPLA2 MICU1 NACC1 CAPN1 RNASEH2C WARS1 VAMP1 TRNW CYP2R1 FGF14 KLHL41 CHCHD10 DES HK1 TPM3 SMARCE1 MORC2 DARS2 FDX2 BAP1 ATP6V1A FOXG1 CDK8 ARV1 HCN1 CLTC ERCC8 SZT2 BICD2 VCP GABRA5 USP9X AP4M1 NDUFS8 TK2 TAF1 GOSR2 KLHL41 CCN6 SQSTM1 ACOX1 SORD SLC1A2 FTL FLRT1 GABRB2 MARCHF6 CACNA1B HSPB3 NEB FKRP SPG11 SGCD FLNC MYPN TPM2 DNM1 DHTKD1 PEX6 MATN3 NTRK2 PRX ACTA1 CDK19 KCNJ10 SLC5A7 INTS1 MYF6 RARS1 GRIN2D PUS3 ACTA1 ARL6IP1 CYP27B1 GFPT1 MFN2 ACTL6B SNAP25 GALC POMT1 GRID2 ERCC8 TTBK2 HSPB1 KCNB1 DNA2 MED25 PLEKHG5 ALG2 FA2H MYOT B4GALNT1 AP4E1 KCNC3 YWHAG MIEF2 FA2H CHAT TCAP RSPRY1 SURF1 DLAT ORAI1 SLC25A1 AP4S1 HACE1 TERT TREX1 TIA1 GABRB2 PIK3CA ARSA RTN2 IFIH1 PPP3CA MATR3 ARL6IP1 RAB11B TPP1 PNPLA2 NF2 SAMHD1 KBTBD13 ALS2 DPAGT1 LRP4 WARS2 SUFU ERLIN1 ATRX HK1 MYH7 MYO9A DALRD3 CYFIP2 KCNA2 BAP1 KCNA2 FHL1 GLE1 GJB1 COL13A1 SLC18A3 TRAK1 MECP2 ATP6 COASY UBA5 C19ORF12 SLC25A19 SMARCB1 SBF2 MORC2 VCP DDHD1 SLC2A3 TRAPPC11 HPCA CDKL5 PARS2 ALG14 SLC34A3 RNASEH2B TRAPPC11 ARSI MSTO1 GABRA2 REEP1 SACS DHDDS ADCY5 CAPN3 DAG1 BVES NKX6-2 ERCC6 SYNGAP1 CAPN3 GBA2 SPART KY NOP56 PLP1 ELOVL5 AP3B2 AKT1 KLHL9 MSTO1 TPM2 GPAA1 ADAR NUS1 SLC5A7 SH3TC2 HTT SYT2 PMP2 ERLIN1 TGM6 PGAP1 ERCC8 MTMR14 TRAF7 SETX GAN FGF12 RNASEH2A CIZ1 DNM1 GPT2 SGCB DDX6 ERCC1 ATP7B SLC52A2 LRP12 WDR48 DNM2 SCN3A GMPPB TBC1D23 BIN1 TIA1 DYSF PLP1 KLC2 ABHD5 SLC13A5 DMD ASAH1 SNAP25 CYP2R1 C12ORF65 VDR IBA57 ERCC4 CRPPA RNU12 PYCR2 TPM3 STRADA STUB1 FUS CYP27B1 AGRN SCN8A MICU1 TTN POMT2 SLC18A3 ABCD1 ASAH1 SPG21
    Protein Mutations 0
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0002355: Difficulty walking
    Genes 304
    C12ORF65 EEF1A2 FBXO38 CRYAB GYG1 WASHC5 TRAPPC11 PLP1 VAMP1 NECAP1 NUBPL ERCC6 NEB CPT1C SMO ANO5 CNKSR2 TTN NTRK1 PDK3 GABRG2 SIGMAR1 TGM6 FKRP FKRP EIF2S3 GJC2 ATP13A2 CACNA1A STXBP1 ALG14 SLC30A10 PDGFB POMT1 RYR1 POMT1 AP4B1 PLP1 DNM1L ERCC6 AARS1 KCND3 SLC30A9 WWOX NKX2-1 ATP13A2 SYNJ1 HERC1 FKTN PSAP CPT1C PNPLA2 MICU1 NACC1 CAPN1 RNASEH2C WARS1 VAMP1 TRNW CYP2R1 FGF14 KLHL41 CHCHD10 DES HK1 TPM3 SMARCE1 MORC2 DARS2 FDX2 BAP1 ATP6V1A FOXG1 CDK8 ARV1 HCN1 CLTC ERCC8 SZT2 BICD2 VCP GABRA5 USP9X AP4M1 NDUFS8 TK2 TAF1 GOSR2 KLHL41 CCN6 SQSTM1 ACOX1 SORD SLC1A2 FTL FLRT1 GABRB2 MARCHF6 CACNA1B HSPB3 NEB FKRP SPG11 SGCD FLNC MYPN TPM2 DNM1 DHTKD1 PEX6 MATN3 NTRK2 PRX ACTA1 CDK19 KCNJ10 SLC5A7 INTS1 MYF6 RARS1 GRIN2D PUS3 ACTA1 ARL6IP1 CYP27B1 GFPT1 MFN2 ACTL6B SNAP25 GALC POMT1 GRID2 ERCC8 TTBK2 HSPB1 KCNB1 DNA2 MED25 PLEKHG5 ALG2 FA2H MYOT B4GALNT1 AP4E1 KCNC3 YWHAG MIEF2 FA2H CHAT TCAP RSPRY1 SURF1 DLAT ORAI1 SLC25A1 AP4S1 HACE1 TERT TREX1 TIA1 GABRB2 PIK3CA ARSA RTN2 IFIH1 PPP3CA MATR3 ARL6IP1 RAB11B TPP1 PNPLA2 NF2 SAMHD1 KBTBD13 ALS2 DPAGT1 LRP4 WARS2 SUFU ERLIN1 ATRX HK1 MYH7 MYO9A DALRD3 CYFIP2 KCNA2 BAP1 KCNA2 FHL1 GLE1 GJB1 COL13A1 SLC18A3 TRAK1 MECP2 ATP6 COASY UBA5 C19ORF12 SLC25A19 SMARCB1 SBF2 MORC2 VCP DDHD1 SLC2A3 TRAPPC11 HPCA CDKL5 PARS2 ALG14 SLC34A3 RNASEH2B TRAPPC11 ARSI MSTO1 GABRA2 REEP1 SACS DHDDS ADCY5 CAPN3 DAG1 BVES NKX6-2 ERCC6 SYNGAP1 CAPN3 GBA2 SPART KY NOP56 PLP1 ELOVL5 AP3B2 AKT1 KLHL9 MSTO1 TPM2 GPAA1 ADAR NUS1 SLC5A7 SH3TC2 HTT SYT2 PMP2 ERLIN1 TGM6 PGAP1 ERCC8 MTMR14 TRAF7 SETX GAN FGF12 RNASEH2A CIZ1 DNM1 GPT2 SGCB DDX6 ERCC1 ATP7B SLC52A2 LRP12 WDR48 DNM2 SCN3A GMPPB TBC1D23 BIN1 TIA1 DYSF PLP1 KLC2 ABHD5 SLC13A5 DMD ASAH1 SNAP25 CYP2R1 C12ORF65 VDR IBA57 ERCC4 CRPPA RNU12 PYCR2 TPM3 STRADA STUB1 FUS CYP27B1 AGRN SCN8A MICU1 TTN POMT2 SLC18A3 ABCD1 ASAH1 SPG21
    Protein Mutations 0
    SNP 0

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook